These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 16400341)
21. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214 [TBL] [Abstract][Full Text] [Related]
22. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM; Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058 [TBL] [Abstract][Full Text] [Related]
23. New classification of chronic GVHD: added clarity from the consensus diagnoses. Arora M; Nagaraj S; Witte J; DeFor TE; MacMillan M; Burns LJ; Weisdorf DJ Bone Marrow Transplant; 2009 Jan; 43(2):149-53. PubMed ID: 18794869 [TBL] [Abstract][Full Text] [Related]
24. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Chang YJ; Zhao XY; Huang XJ Biol Blood Marrow Transplant; 2008 Mar; 14(3):323-34. PubMed ID: 18275899 [TBL] [Abstract][Full Text] [Related]
25. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies. Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633 [TBL] [Abstract][Full Text] [Related]
26. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
27. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Busca A; Locatelli F; Marmont F; Ceretto C; Falda M Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391 [TBL] [Abstract][Full Text] [Related]
28. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation. Kim DH; Popradi G; Xu W; Gupta V; Kuruvilla J; Wright J; Messner HA; Lipton JH Biol Blood Marrow Transplant; 2009 Apr; 15(4):471-82. PubMed ID: 19285635 [TBL] [Abstract][Full Text] [Related]
29. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125 [TBL] [Abstract][Full Text] [Related]
30. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation]. Lin Q; Dong M; Wang QM; Wen JY; Wu XY Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772 [TBL] [Abstract][Full Text] [Related]
31. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
32. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687 [TBL] [Abstract][Full Text] [Related]
33. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse. Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638 [TBL] [Abstract][Full Text] [Related]
34. Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Martin SJ; Audrain MA; Oksman F; Ecoiffier M; Attal M; Milpied N; Esnault VL Bone Marrow Transplant; 1997 Jul; 20(1):45-8. PubMed ID: 9232255 [TBL] [Abstract][Full Text] [Related]
35. Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation. Inamoto Y; Nishida T; Suzuki R; Miyamura K; Sao H; Iida H; Naoe T; Maruyama F; Hirabayashi N; Hamaguchi M; Iseki T; Kami M; Yano K; Takeyama H; Morishita Y; Morishima Y; Kodera Y Bone Marrow Transplant; 2007 Jan; 39(1):25-30. PubMed ID: 17115063 [TBL] [Abstract][Full Text] [Related]
36. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917 [TBL] [Abstract][Full Text] [Related]
37. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971 [TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Akpek G; Chinratanalab W; Lee LA; Torbenson M; Hallick JP; Anders V; Vogelsang GB Biol Blood Marrow Transplant; 2003 Jan; 9(1):46-51. PubMed ID: 12533741 [TBL] [Abstract][Full Text] [Related]
39. A retrospective review of the outcome after second or subsequent allogeneic transplantation. Kedmi M; Resnick IB; Dray L; Aker M; Samuel S; Gesundheit B; Slavin S; Or R; Shapira MY Biol Blood Marrow Transplant; 2009 Apr; 15(4):483-9. PubMed ID: 19285636 [TBL] [Abstract][Full Text] [Related]
40. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Labbé AC; Su SH; Laverdière M; Pépin J; Patiño C; Cohen S; Kiss T; Lachance S; Sauvageau G; Busque L; Roy DC; Roy J Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]